Format

Send to

Choose Destination
Stem Cells Transl Med. 2014 Aug;3(8):879-87. doi: 10.5966/sctm.2014-0122. Epub 2014 Jul 18.

Proceedings: international regulatory considerations on development pathways for cell therapies.

Author information

1
California Institute for Regenerative Medicine, San Francisco, California, USA; efeigal@cirm.ca.gov.
2
Janssen Research and Development, LLC, Spring House, Pennsylvania, USA;
3
Princess Margaret Cancer Centre and Centre for Commercialization of Regenerative Medicine, Toronto, Ontario, Canada;
4
GE Healthcare, Exton, Pennsylvania, USA;
5
California Institute for Regenerative Medicine, San Francisco, California, USA;
6
Medical Research Council, London, United Kingdom;
7
Cell Therapy Catapult Ltd., Guy's Hospital, London, United Kingdom.

Abstract

Regenerative medicine is a rapidly evolving field that faces novel scientific and regulatory challenges. In September 2013, the International Workshop on Regulatory Pathways for Cell Therapies was convened to discuss the nature of these challenges and potential solutions and to highlight opportunities for potential convergence between different regulatory bodies that might assist the field's development. The workshop discussions generated potentially actionable steps in five main areas that could mitigate cell therapy development pathway risk and accelerate moving promising therapies to patients. These included the need for convergence of regulatory guidelines on donor eligibility and suitability of lines for use in clinical trials and subsequent commercialization for cell therapies to move forward on a global basis; the need to challenge and encourage investigators in the regenerative medicine field to share information and provide examples of comparability studies related to master cell banks; the need for convergence of guidelines across regulatory jurisdictions on requirements for tumorigenicity studies, based on particular cell types and on biodistribution studies; the need to increase transparency in sharing clinical trial information more broadly and disseminating results more rapidly; and the need to establish a forum for sharing the experiences of various approaches being developed to expedite regulatory approvals and access for patients to innovative cell and regenerative therapies in the different regulatory jurisdictions and to assess their potential strengths and weaknesses.

KEYWORDS:

Cell therapy; Stem cells; U.S. Food and Drug Administration

PMID:
25038248
PMCID:
PMC4116253
DOI:
10.5966/sctm.2014-0122
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center